Key Takeaways Walgreens Boots Alliance stock plummeted to a 27-year low on Thursday after the pharmacy chain and healthcare provider missed profit estimates and slashed its outlook amid weakening consumer demand. Walgreens shares started their long-term downtrend after toping out in August 2015, with the decline accelerating from July 2022 following a death cross, a bearish chart pattern that signals lower prices. Walgreens' share price may reclaim the $14 level near a 1997 price peak in the short-term due ...

Walgreens Boots Alliance NASDAQ: WBA is a global leader in integrated healthcare, pharmacy, and retail. The company recently released its earnings report for the third quarter of 2024, raising questions about its ability to navigate a challenging market environment and achieve sustainable growth. Walgreens Boots Alliance Today WBA Walgreens Boots Alliance $12.19 -3.47 (-22.16%) 52-Week Range $11.68 ▼ $31.32 Dividend Yield 8.20% Price Target $23.07 Add to Watchlist The company’s expansive network of approxim ...

Key Takeaways The S&P 500 edged 0.1% higher on Thursday, June 27, 2024, ahead of key inflation data set for release on Friday. Shares of server and data storage provider Super Micro Computer moved higher as the company aims to sustain its strong growth trajectory. Walgreens Boots Alliance shares tumbled after the pharmacy giant missed quarterly earnings estimates and announced it would close underperforming stores. Major U.S. equities indexes posted moderate gains on Thursday ahead of Friday's Personal Cons ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended May 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From _______to _______ Commission File Number 001-36759 WALGREENS BOOTS ALLIANCE, INC. (Exact name of registrant as specified in its charter) Delaware 47-1758322 (State ...

Management continues to lower expectations. Shares of pharmacy Walgreens Boots Alliance (WBA -23.85%) fell as much as 25.4% in trading on Thursday after reporting fiscal third-quarter 2024 results. Shares are still down 24.7% at 3 p.m. ET. Weaker than expected results Management said revenue was up 2.6% to $36.4 billion, and net income nearly tripled to $344 million, or $0.40 per share. The big change was earnings guidance for the full year being cut from a range of $3.20 to $3.35 down to a range of $2.80 t ...

Challenges in the retail environment and the pharmacy industry have led Walgreens Boots Alliance to consider closing as many as 25% of its U.S. retail stores. These Walgreens stores do not contribute to the firm’s adjusted operating income, and the company expects that a “significant portion” of these underperforming stores will be closed over the next three years, Walgreens Boots Alliance CEO Tim Wentworth said Thursday (June 27) during the company’s quarterly earnings call. For the remainder of those unde ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

HONG KONG, CHINA - 2024/06/21: In this photo illustration, the American pharmacy chain Walgreens ... [+] (NASDAQ: WBA) logo seen displayed on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images) SOPA Images/LightRocket via Getty Images Walgreens recently reported its Q3’24 results (fiscal ends in August), with revenue exceeding but earnings falling short of our expectations. The company reported revenue of ...

Walgreens on Thursday said it could shutter up to a quarter of its more than 8,600 US locations amid plunging retail sales as inflation-battered shoppers cut back on spending. The struggling drug store chain, which closed 150 US locations last year, cut its profit forecast ahead of reporting its quarterly earnings — sending the company’s stock plummeting by nearly 25% in mid-day trading. Walgreens CEO Tim Wentworth, who took over the 123-year-old company in October, cited “persistent pressures on the US con ...

财务数据和关键指标变化 - 第三季度销售额增长2.5%,其中美国零售药房业务增长2.3%,国际业务增长1.6%,美国医疗保健业务增长7.6% [33] - 调整后每股收益为0.63美元,同比下降37%,主要受到较低的售后租回收益、美国零售环境挑战和最近的药房行业趋势的影响 [34] - 前9个月销售额增长5.6%,调整后每股收益下降25%,主要受到美国零售药房业务表现疲软和售后租回收益大幅下降的影响,部分被成本节约措施、美国医疗保健业务盈利能力提升和较低的调整后有效税率所抵消 [36] 各条业务线数据和关键指标变化 美国零售药房 - 可比销售额增长3.5%,主要受到品牌通胀和药房及处方量增长的推动,但零售销售下降 [38] - 调整后营业利润下降48%,主要受到较低的售后租回收益、上年度减少的激励计提和Cencora股权收益下降的影响 [38-39] - 药房可比销售额增长5.7%,处方量(不含疫苗)增长1.7%,与整体市场增长保持一致 [41] - 药房调整后毛利率下降,受到品牌组合影响、报销压力、新冠检测需求下降和某些仿制药采购动态类似品牌药的影响 [42] 美国零售 - 可比零售销售下降2.3%,消费者环境持续疲软,公司采取了降价促销措施以提振销量和客户忠诚度 [43] - 零售毛利率下降,受到价格和促销投资以及去年毛利率恢复措施的影响,部分被类别绩效改善举措带来的正面影响所抵消 [43-44] 国际 - 总销售额增长1.6%,英国Boots业务销售额增长1.6%,德国批发业务增长4.9% [46] - 调整后营业利润下降17%,主要受到去年同期房地产收益的影响 [46] 美国医疗保健 - 销售额增长7.6%,达到21亿美元,VillageMD销售额增长7%,Shields销售额增长24% [47] - 调整后EBITDA为2300万美元,同比改善1.36亿美元,受益于VillageMD成本优化和Shields持续强劲增长 [47] 各个市场数据和关键指标变化 - 处方量市场整体增长低于预期,主要受到Medicaid重新认定的影响 [41] - 英国Boots业务处方销售额增长5.8%,零售销售额增长6%,线上销售占比近16% [46] 公司战略和发展方向及行业竞争 - 公司正在简化和聚焦业务,利用与客户的核心关系以资本高效的方式进入相邻领域,并寻找机会实现盈利增长、产生充足现金流和加强战略相关业务 [59-60] - 零售药房体验在未来将更加重要,但需要演变,公司正在采取多项措施改善客户体验,包括优化门店网络、调整商品组合、加强数字化和忠诚度计划等 [61-70] - 公司正在与支付方和PBM进行积极对话,以确保获得公平的报酬,同时也在与供应商合作拓展专科药房、临床试验等服务 [25-26][148] - 公司正在评估各项非零售药房资产,优先考虑战略适配性、利润增长潜力和现金流产生能力,并将停止一些分散注意力的举措,专注于创造长期股东价值的领域 [76-80] 管理层对经营环境和未来前景的评论 - 消费者环境持续疲软,客户变得更加选择性和价格敏感,公司采取了降价促销措施以提振销量和客户忠诚度 [21-22][50] - 药房行业面临的挑战持续加剧,包括品牌组合影响、监管和报销压力增加,以及NADAC价格波动 [23-24][42-43] - 处方量市场增长虽有所增加,但仍低于疫情前水平 [24][41] - 公司预计未来经营环境仍将充满挑战,不会出现美国零售环境改善,处方量增长将保持平缓,药房利润率将继续承压 [29-30][50-51] 其他重要信息 - 公司正在进行战略和运营审查,已经采取一系列行动应对挑战,包括优化门店网络、提升客户体验、改善药房服务等 [18-19][63-72] - 公司正在重组组织架构,以提高效率和更好地为行业合作伙伴提供服务 [73-75] - 公司维持全年调整后EBITDA在盈亏平衡水平的中值预期不变,调整后有效税率预计低于5% [52] - 公司计划在未来3年内关闭大部分表现不佳的门店,并采取措施提升其余门店的盈利能力和客户体验 [64-66] - 公司将继续投资于Boots UK业务,并与VillageMD合作寻求更快速地释放流动性和增强灵活性 [77-80] 问答环节重要的提问和回答 问题1 **Lisa Gill 提问** 未来零售药房的定位是什么?公司与支付方和PBM的对话进展如何? [85-86] **Tim Wentworth 和 Mary Langowski 回答** - 零售药房未来将更加重要,但需要演变,公司正在采取多项措施改善客户体验,包括优化门店网络、调整商品组合、加强数字化和忠诚度计划等 [87-91] - 公司正在与支付方和PBM进行积极对话,以确保获得公平的报酬,双方都认识到现有模式需要改变 [148] 问题2 **Charles Rhyee 提问** 关闭25%表现不佳门店的具体计划和影响 [100-101] **Tim Wentworth 和 Tracey Brown 回答** - 关店决策考虑多方面因素,包括消费者趋势、